2021 Fiscal Year Final Research Report
Development of molecular targeted drug using high-resolution epitope mapping: a novel therapeutic strategy for intraocular fibrotic scarring
| Project/Area Number |
19K07387
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 49010:Pathological biochemistry-related
|
|---|
| Research Institution | Gifu Pharmaceutical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
鎌田 春彦 国立研究開発法人医薬基盤・健康・栄養研究所, 医薬基盤研究所 創薬デザイン研究センター, プロジェクトリーダー (00324509)
原 英彰 岐阜薬科大学, 薬学部, 学長 (20381717)
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Keywords | 加齢黄斑変性 / 脈絡膜血管新生 / 線維性瘢痕 / 線維化 / 網膜色素上皮細胞 |
|---|
| Outline of Final Research Achievements |
In the retinal pigment epithelium of laser-induced choroidal neovascularization model mice, protein X was clearly localized in or near collagen -1 labeled fibrotic scars. In addition, it was clarified that Protein X has an action of promoting fibrosis of retinal pigment epithelial cells. The functional epitope region structure in Protein X was specified, and it succeeded in creating the functional antibody which is more excellent in the neutralizing activity than the existing antibody.
|
| Free Research Field |
薬理学
|
| Academic Significance and Societal Importance of the Research Achievements |
滲出型加齢黄斑変性の慢性期では、脈絡膜血管新生に伴う線維性瘢痕が形成され、不可逆的な視力低下を引き起こすことが知られる。しかし、眼内線維化病態の発症及び進行を防ぐ治療法は未だ確立されていない。本研究で作製した抗X抗体は線維性瘢痕を対象にした滲出型加齢黄斑変性の長期治療マネジメントに有用な治療薬になる可能性が期待できる。
|
